I'll follow FDA Guidance for tumor cancer endpoints. PFS was the PRIMARY endpoint. They failed to met it and tossed it out and declared naive OS as the new primary endpoint -- although NWBO has repeatedly reported the data was confounded. Then NWBO post hoc data dredged recurrent OS n=64.
Lot's of trial manipulation for regulators to sort out. Most not reported to medical community so they don't know better.
Market Data 
Markets 
AI
